Novophage Secures $5.7 Million Series A Funding  

Flybridge Capital Partners, Chevron Technology Ventures, Founder Collective, The Kraft Group and Boston University Invest

Novophage named part of prestigious “12x12” program

BOSTON, MA – June 1, 2011 – Novophage, an early-stage technology company that is developing a new class of industrial biologics, announced today that it has completed a $5.7 million Series A round of financing. Flybridge Capital Partners led the investment round, which also included participation from Founder Collective, Boston University (BU) and strategic investors, Chevron Technology Ventures and The Kraft Group. Concurrent with the funding, Jon Karlen, a General Partner at Flybridge Capital Partners, will join the company’s Board of Directors and Vinit Nijhawan, Managing Director of the Office of Technology Development at BU will join the Board as an Observer.

The company is bringing the industrial sector the same breakthroughs in genetic sequencing and engineering that have revolutionized biotech and biofuels. Novophage will develop and market synthetic biology-enabled products that tackle the problems of bacterial contamination in industries such as oil and gas, pulp and paper and HVAC systems. The company’s products will improve productivity, reduce infrastructure corrosion and improve the overall environmental impact of these water-intensive industries. 

As part of the funding, Micah Rosenbloom has joined the company as CEO.  Rosenbloom is the co-founder of Brontes Technologies, which was backed by Flybridge Capital Partners and co-founded by Founder Collective’s Eric Paley. Brontes Technologies was sold to 3M in 2006.

Read more...